At the time of writing, Perspective Therapeutics Inc [CATX] stock is trading at $2.50, down -1.57%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CATX shares have gain 6.38% over the last week, with a monthly amount drifted -24.47%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Perspective Therapeutics Inc [AMEX: CATX] stock has seen the most recent analyst activity on March 07, 2025, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $15. Previously, BofA Securities downgraded its rating to Neutral on November 25, 2024, and dropped its price target to $5. On October 24, 2024, UBS initiated with a Buy rating and assigned a price target of $20 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $25 on October 01, 2024. Truist initiated its recommendation with a Buy and recommended $21 as its price target on September 25, 2024. BofA Securities started tracking with a Buy rating for this stock on July 25, 2024, and assigned it a price target of $24. In a note dated May 09, 2024, Cantor Fitzgerald initiated an Overweight rating.
For the past year, the stock price of Perspective Therapeutics Inc fluctuated between $2.32 and $19.05. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Perspective Therapeutics Inc [AMEX: CATX] shares were valued at $2.50 at the most recent close of the market. An investor can expect a potential return of 740.0% based on the average CATX price forecast.
Analyzing the CATX fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -159.37%, Pretax Profit Margin comes in at -139.74%, and Net Profit Margin reading is -189.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.26 and Total Capital is -0.15. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.42 points at the first support level, and at 2.34 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.58, and for the 2nd resistance point, it is at 2.66.
Ratios To Look Out For
It is important to note that Perspective Therapeutics Inc [AMEX:CATX] has a current ratio of 9.60. Also, the Quick Ratio is 9.60, while the Cash Ratio stands at 8.05.
Transactions by insiders
Recent insider trading involved HENSON HEIDI, Director, that happened on Dec 04 ’24 when 25975.0 shares were purchased. CEO, Spoor Johan M. completed a deal on Dec 04 ’24 to buy 8000.0 shares. Meanwhile, Director Williamson Robert F III bought 6266.0 shares on Nov 25 ’24.
